Paine Schwartz Partners, a global leader in sustainable food chain investing, announced that it has entered into a definitive agreement with respect to a new strategic investment by Paine Schwartz Food Chain Fund V in Hendrix Genetics, a leading multi-species animal genetics, and technology company. Paine Schwartz and its affiliated co-investors will hold 50% ownership in the Company. Hendrix Genetics’ Co-Founders, Thijs Hendrix and Antoon van den Berg will also maintain a 50% ownership position in the Company and work in partnership with Paine Schwartz to drive the business forward. Investment firm NPM Capital, a shareholder in the Company since 2015, will sell its minority interest as an integral part of this transaction. The financial terms of the transaction were not disclosed.
“We are excited to partner with the Paine Schwartz team to build on our strong foundation and further grow by continuing to develop innovative solutions for the animal protein sector that meet the challenges of food production,” said Thijs Hendrix.
Kevin Schwartz, Chief Executive Officer of Paine Schwartz, said, “This strategic investment in Hendrix Genetics is directly aligned with our long-term thesis of identifying companies that sustainably increase productivity in the production of agriculture commodities, which is required to feed an ever-growing global population. We are pleased to be joined in this investment by co-investors who also recognize the significant value creation opportunity ahead for Hendrix Genetics and its data and technology-enabled breeding programs. We look forward to working in partnership with Thijs and Antoon to support Jolanda and the entire Hendrix Genetics team to drive the Company’s next phase of growth.”
This strategic investment builds on Paine Schwartz’s longstanding track record of partnering with family or founder-owned companies, as well as investing in the upstream sustainable food chain segments of genetics and animal health and nutrition, which includes companies such as SNFL, Advanta, Seminis, Verisem, and Axiota Animal Health.
The transaction is expected to close by the end of the first quarter of 2022, subject to regulatory approval and customary closing conditions.
